Department of Nephrology and Dialysis, L. Parodi-Delfino Hospital, Colleferro, Rome, Italy -
Department of Research, Innovation, Brand Reputation, Bergamo Hospital, ASST Papa Giovanni XXIII, Bergamo, Italy.
Minerva Cardioangiol. 2020 Jun;68(3):188-196. doi: 10.23736/S0026-4725.20.05078-1. Epub 2020 Feb 20.
Diabetes mellitus, with its complications, is one of the major health problems in economically developed countries and its prevalence is constantly increasing. Kidneys and heart involvement represent main comorbidities in diabetic patients often leading to organ failure. The treatments available until a few years ago are often associated with hypoglycemia, weight gain, gastro-intestinal disorders and other side effects together with serious adverse effects on renal function. The new frontiers of diabetic cardionephropathy treatment are mainly focused on delay of heart and renal failure both on diabetic and nondiabetic patients ad it was shown by last data reports. In the following review, we will focus on Gliflozins, one of the newest classes of hypoglycemic drugs that have shown to hold peculiar pharmacological properties in managing cardiac and renal complications.
糖尿病及其并发症是经济发达国家的主要健康问题之一，其患病率不断上升。肾脏和心脏受累是糖尿病患者的主要合并症，常导致器官衰竭。几年前可用的治疗方法常伴有低血糖、体重增加、胃肠道紊乱和其他副作用，以及对肾功能的严重不良影响。糖尿病心肾并发症治疗的新领域主要集中在延缓糖尿病和非糖尿病患者的心肾衰竭，这是最近的数据报告所显示的。在下面的综述中，我们将重点介绍格列净类药物，这是最新的一类降糖药物，具有管理心脏和肾脏并发症的独特药理特性。
